Annovis Bio, a Phase 3 clinical-stage biotechnology company developing investigational treatments for neurodegenerative diseases, has received a US patent for a new crystalline form of buntanetap, its investigational oral therapy for Alzheimer's disease (AD) and Parkinson's Disease (PD). The United States Patent and Trademark Office (USPTO) issued US Patent No. 12,780,831, titled ‘Solid Forms of Posiphen D-Tartrate’, covering the new crystalline form designated as Form B.
The patent includes 11 claims covering the Form B solid form, its crystalline characteristics identified through X-ray powder diffraction and crystal unit cell analysis, and its high-purity composition exceeding 99.5 , percent as determined by High-Performance Liquid Chromatography (HPLC). It also covers methods for preparing Form B from the previously used anhydrous Form A, as well as pharmaceutical compositions containing Form B and a pharmaceutically acceptable carrier. The patent provides protection for buntanetap Form B through June 21, 2044.
According to the company, Form B is a highly crystalline dihydrate, while the earlier Form A is a semi-crystalline anhydrate. The two forms have distinct crystalline phases and do not readily convert into one another. Form B has demonstrated stability under different processing conditions, including vacuum drying and milling, without changes in its crystalline structure or form. HPLC analysis has reported a purity level of 99.9 percent.
Pharmacokinetic comparisons conducted in mice, dogs and humans showed comparable profiles for Form B and Form A across plasma, brain and cerebrospinal fluid. The findings were submitted to the US Food and Drug Administration (FDA) and published in the peer-reviewed journal Biomolecules.
Maria Maccecchini, PhD, Founder, President and CEO of Annovis Bio, said the patent strengthens the company's intellectual property position as it advances buntanetap through clinical development and prepares for regulatory submissions. She noted that the patent covers Form B, which is being used in the company's ongoing clinical programme.
The patent follows the company's earlier regulatory and development milestones. Annovis filed a composition-of-matter patent application covering new solid forms of buntanetap in June 2024. In July 2024, the FDA cleared the transition to the new crystalline form in future clinical trials after reviewing bridging studies comparing Form A and Form B, along with manufacturing data for the new form.
Annovis has completed enrolment in its pivotal Phase 3 clinical trial (NCT06709014), evaluating once-daily oral buntanetap Form B at a 30 mg dose in patients with early Alzheimer's disease who test positive for the plasma biomarker pTau217. The trial includes two pre-specified assessments: a six-month analysis of symptomatic effects and an 18-month analysis of potential disease-modifying effects.
The company expects to report top-line results from the symptomatic analysis in the first quarter of 2027, followed by the disease-modifying analysis in the first quarter of 2028. Annovis has also begun preparations for New Drug Application (NDA) submissions following the respective trial readouts.
Buntanetap, formerly known as posiphen, is an investigational once-daily oral therapy designed to inhibit the production of multiple neurotoxic proteins, including Amyloid Precursor Protein (APP), amyloid beta, tau, alpha-synuclein and TDP-43, through an RNA-targeting mechanism. The company is developing the therapy to address underlying mechanisms associated with neurodegeneration and potentially slow disease progression.
Last news about this category
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy